Literature DB >> 26188004

Retinitis pigmentosa: impact of different Pde6a point mutations on the disease phenotype.

Vithiyanjali Sothilingam1, Marina Garcia Garrido1, Kangwei Jiao2, Elena Buena-Atienza3, Ayse Sahaboglu4, Dragana Trifunović4, Sukirthini Balendran3, Tanja Koepfli3, Regine Mühlfriedel1, Christian Schön5, Martin Biel5, Angelique Heckmann6, Susanne C Beck1, Stylianos Michalakis5, Bernd Wissinger3, Mathias W Seeliger1, François Paquet-Durand7.   

Abstract

Mutations in the PDE6A gene can cause rod photoreceptors degeneration and the blinding disease retinitis pigmentosa (RP). While a number of pathogenic PDE6A mutations have been described, little is known about their impact on compound heterozygous situations and potential interactions of different disease-causing alleles. Here, we used a novel mouse model for the Pde6a R562W mutation in combination with an existing line carrying the V685M mutation to generate compound heterozygous Pde6a V685M/R562W animals, exactly homologous to a case of human RP. We compared the progression of photoreceptor degeneration in these compound heterozygous mice with the homozygous V685M and R562W mutants, and additionally with the D670G line that is known for a relatively mild phenotype. We investigated PDE6A expression, cyclic guanosine mono-phosphate accumulation, calpain and caspase activity, in vivo retinal function and morphology, as well as photoreceptor cell death and survival. This analysis confirms the severity of different Pde6a mutations and indicates that compound heterozygous mutants behave like intermediates of the respective homozygous situations. Specifically, the severity of the four different Pde6a situations may be categorized by the pace of photoreceptor degeneration: V685M (fastest) > V685M/R562W > R562W > D670G (slowest). While calpain activity was strongly increased in all four mutants, caspase activity was not. This points to the execution of non-apoptotic cell death and may lead to the identification of new targets for therapeutic interventions. For individual RP patients, our study may help to predict time-courses for Pde6a-related retinal degeneration and thereby facilitate the definition of a window-of-opportunity for clinical interventions.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26188004     DOI: 10.1093/hmg/ddv275

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  18 in total

1.  Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B.

Authors:  Samer Khateb; Marco Nassisi; Kinga M Bujakowska; Cécile Méjécase; Christel Condroyer; Aline Antonio; Marine Foussard; Vanessa Démontant; Saddek Mohand-Saïd; José-Alain Sahel; Christina Zeitz; Isabelle Audo
Journal:  JAMA Ophthalmol       Date:  2019-06-01       Impact factor: 7.389

Review 2.  Calpains as mechanistic drivers and therapeutic targets for ocular disease.

Authors:  Jennifer T Vu; Elena Wang; Jolan Wu; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Soo Hyeon Lee; Vinit B Mahajan
Journal:  Trends Mol Med       Date:  2022-05-29       Impact factor: 15.272

3.  Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa.

Authors:  Laura Kuehlewein; Torsten Straßer; Gunnar Blumenstock; Katarina Stingl; M Dominik Fischer; Barbara Wilhelm; Eberhart Zrenner; Bernd Wissinger; Susanne Kohl; Nicole Weisschuh; Ditta Zobor
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.925

4.  Reproducibility of the Rod Photoreceptor Response Depends Critically on the Concentration of the Phosphodiesterase Effector Enzyme.

Authors:  Ala Morshedian; Gabriela Sendek; Sze Yin Ng; Kimberly Boyd; Roxana A Radu; Mingyao Liu; Nikolai O Artemyev; Alapakkam P Sampath; Gordon L Fain
Journal:  J Neurosci       Date:  2022-01-28       Impact factor: 6.709

5.  TNFa knockdown in the retina promotes cone survival in a mouse model of autosomal dominant retinitis pigmentosa.

Authors:  Tapasi Rana; Pravallika Kotla; Roderick Fullard; Marina Gorbatyuk
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-11-14       Impact factor: 5.187

6.  Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations.

Authors:  K Jiao; A Sahaboglu; E Zrenner; M Ueffing; P A R Ekström; F Paquet-Durand
Journal:  Cell Death Discov       Date:  2016-07-04

7.  Pyruvate kinase M2 regulates photoreceptor structure, function, and viability.

Authors:  Ammaji Rajala; Yuhong Wang; Richard S Brush; Kristine Tsantilas; Connor S R Jankowski; Ken J Lindsay; Jonathan D Linton; James B Hurley; Robert E Anderson; Raju V S Rajala
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

8.  A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy.

Authors:  Takaaki Hayashi; Kei Mizobuchi; Shuhei Kameya; Kazutoshi Yoshitake; Takeshi Iwata; Tadashi Nakano
Journal:  Doc Ophthalmol       Date:  2021-02-21       Impact factor: 2.379

Review 9.  Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss.

Authors:  Gayle B Collin; Navdeep Gogna; Bo Chang; Nattaya Damkham; Jai Pinkney; Lillian F Hyde; Lisa Stone; Jürgen K Naggert; Patsy M Nishina; Mark P Krebs
Journal:  Cells       Date:  2020-04-10       Impact factor: 7.666

10.  Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa.

Authors:  Freya M Mowat; Laurence M Occelli; Joshua T Bartoe; Kristen J Gervais; Ashlee R Bruewer; Janice Querubin; Astra Dinculescu; Sanford L Boye; William W Hauswirth; Simon M Petersen-Jones
Journal:  Front Neurosci       Date:  2017-06-20       Impact factor: 5.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.